{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:42:54Z","timestamp":1679373774548},"reference-count":8,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"DOI":"10.25259\/ijdvl_1161_2021","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T08:52:23Z","timestamp":1665823943000},"page":"130-132","update-policy":"http:\/\/dx.doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Facial Angiofibroma Severity Index: A beneficial tool to evaluate the treatment response in the skin of colour"],"prefix":"10.25259","volume":"89","author":[{"given":"Amrita A","family":"Hongal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sowmya S","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TN","family":"Revathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"10.25259\/IJDVL_1161_2021\/ref-1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/ced.12398","article-title":"Facial Angiofibroma Severity Index (FASI): Reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma","volume":"39","author":"Salido-Vallejo","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_1161_2021\/ref-2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","article-title":"Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: The TREATMENT randomized clinical trial","volume":"154","author":"Koenig","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1161_2021\/ref-3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/2229-5178.105488","article-title":"Topical rapamycin (sirolimus) for facial angiofibromas","volume":"4","author":"Madke","year":"2013","journal-title":"Indian Dermatol Online J"},{"key":"10.25259\/IJDVL_1161_2021\/ref-4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/pde.13204","article-title":"Tuberous sclerosis complex in 29 children: Clinical and genetic analysis and facial angiofibroma responses to topical sirolimus","volume":"34","author":"Wang","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_1161_2021\/ref-5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8404378","article-title":"Sirolimus ointment for facial angiofibromas in individuals with tuberous sclerosis complex","volume":"2017","author":"Amin","year":"2017","journal-title":"Int Sch Res Notices"},{"key":"10.25259\/IJDVL_1161_2021\/ref-6","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left\u2013right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex","volume":"169","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1161_2021\/ref-7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/0019-5154.174087","article-title":"Use of topical rapamycin in facial angiofibromas in Indian skin type","volume":"61","author":"Viswanath","year":"2016","journal-title":"Indian Journal of Dermatology"},{"key":"10.25259\/IJDVL_1161_2021\/ref-8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/ijdd.ijdd_21_18","article-title":"Topical sirolimus in facial angiofibroma","volume":"4","author":"Gajjar","year":"2018","journal-title":"Indian Journal of Drugs in Dermatology"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/facial-angiofibroma-severity-index-a-beneficial-tool-to-evaluate-the-treatment-response-in-the-skin-of-colour\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/facial-angiofibroma-severity-index-a-beneficial-tool-to-evaluate-the-treatment-response-in-the-skin-of-colour\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T11:45:04Z","timestamp":1679312704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/facial-angiofibroma-severity-index-a-beneficial-tool-to-evaluate-the-treatment-response-in-the-skin-of-colour\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":8,"alternative-id":["10.25259\/IJDVL_1161_2021"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1161_2021","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"130"}}